Agile Therapeutics, Inc. (AGRX)

Market Cap	10.43M
Revenue (ttm)	21.57M +32.2%
Net Income	-15.86M
EPS	-3.64
Shares Out	6.90M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,366
Open	1.510
Previous Close	1.510
Day's Range	1.510 - 1.510
52-Week Range	0.200 - 2.630
Beta	1.58
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2024

About AGRX

Agile Therapeutics, Inc., a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 2014
• Employees: 19
• Stock Exchange: OTCMKTS
• Ticker Symbol: AGRX
• Website: https://www.agiletherapeutics.com

Financial Performance

In 2023, AGRX's revenue was $19.59 million, an increase of 80.02% compared to the previous year's $10.88 million. Losses were -$14.47 million, -43.08% less than in 2022.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 29, 2024

Data Sources Report a data error